MedPath

RECORDATI RARE DISEASES

RECORDATI RARE DISEASES logo
🇫🇷France
Ownership
Private
Established
1990-01-01
Employees
251
Market Cap
-
Website
https://www.recordatirarediseases.com

Clinical Trials

14

Active:9
Completed:2

Trial Phases

3 Phases

Phase 1:9
Phase 2:1
Phase 3:1

Drug Approvals

16

EMA:9
NMPA:5
FDA:2

Drug Approvals

Pasireotide Pamoate Microspheres for Injection

Product Name
注射用双羟萘酸帕瑞肽微球
Approval Number
国药准字HJ20250049
Approval Date
Apr 22, 2025
NMPA

Pasireotide Pamoate Microspheres for Injection

Product Name
注射用双羟萘酸帕瑞肽微球
Approval Number
国药准字HJ20250050
Approval Date
Apr 22, 2025
NMPA

Pasireotide Pamoate Microspheres for Injection

Product Name
注射用双羟萘酸帕瑞肽微球
Approval Number
国药准字HJ20250048
Approval Date
Apr 22, 2025
NMPA

Osilodrostat Phosphate Tablets

Product Name
适锐飒
Approval Number
国药准字HJ20240101
Approval Date
Sep 19, 2024
NMPA

Carglumic Acid Dispersible Tablets

Product Name
卡谷氨酸分散片
Approval Number
国药准字HJ20230085
Approval Date
Jun 27, 2023
NMPA

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
9 (81.8%)
Phase 2
1 (9.1%)
Phase 3
1 (9.1%)

Cold Agglutinin Disease Real World Evidence Registry

Recruiting
Conditions
Cold Agglutinin Disease (CAD)
Cold Agglutinin Syndrome (CAS)
Interventions
First Posted Date
2023-03-30
Last Posted Date
2025-05-01
Lead Sponsor
Recordati Rare Diseases
Target Recruit Count
400
Registration Number
NCT05791708
Locations
🇺🇸

University of Alabama at Birmingham Site Number : 1230, Birmingham, Alabama, United States

🇺🇸

SLO Oncology and Hematology Site Number : 1235, San Luis Obispo, California, United States

🇺🇸

Mission Hope Medical Oncology Site Number : 1241, Santa Maria, California, United States

and more 65 locations

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

Recruiting
Conditions
Hyperammonemia
Methylmalonic Acidemia
Propionic Acidemia
Interventions
First Posted Date
2021-09-10
Last Posted Date
2025-04-15
Lead Sponsor
Recordati Rare Diseases
Target Recruit Count
20
Registration Number
NCT05040178
Locations
🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 2 locations

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Phase 2
Completed
Conditions
Neurotrophic Keratitis
Interventions
Other: Vehicle
First Posted Date
2020-02-19
Last Posted Date
2025-05-14
Lead Sponsor
Recordati Rare Diseases
Target Recruit Count
108
Registration Number
NCT04276558
Locations
🇺🇸

Nature Coast Clinical Research, Crystal River, Florida, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

University of Maryland School of Medicine UMSOM, Baltimore, Maryland, United States

and more 38 locations

Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach

Recruiting
Conditions
Methylmalonic Acidemia
Propionic Acidemia
Interventions
First Posted Date
2019-11-25
Last Posted Date
2024-02-05
Lead Sponsor
Recordati Rare Diseases
Target Recruit Count
95
Registration Number
NCT04176523
Locations
🇫🇷

Hopital Des Enfants, CHU de Bordeaux-GH Pellegrin, Bordeaux, France

🇫🇷

Hopital de la Conception, Marseille, France

🇫🇷

Hôpital de la Timone, Marseille, France

and more 29 locations

Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)

Phase 3
Completed
Conditions
Cystinosis
Interventions
First Posted Date
2019-10-14
Last Posted Date
2024-02-05
Lead Sponsor
Recordati Rare Diseases
Target Recruit Count
5
Registration Number
NCT04125927
Locations
🇧🇪

UZ Leuven, Leuven, Belgium

🇫🇷

Hôpital Necker-Enfants Malades, Paris, France

🇩🇪

Klinik für Pädiatrische Nieren, Hannover, Germany

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.